# A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

> **NCT00975481** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 36 (actual)

## Conditions studied

- Alzheimer's Disease
- Huntington's Disease

## Interventions

- **DRUG:** dimebon
- **DRUG:** dimebon
- **DRUG:** dimebon
- **DRUG:** placebo
- **DRUG:** alprazolam
- **DRUG:** alprazolam

## Key facts

- **NCT ID:** NCT00975481
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975481, "A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00975481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*